developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeTagsobesity

#obesity

All articles tagged with "obesity"

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Archive
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

obesity Articles | Developments Today

Obesity in young adulthood linked to increased risk of early-onset cancer

Young-Adult Obesity Linked to Higher Early-Onset Cancer Risk

More than 6 million healthy adults aged 20 to 39 were followed for about a decade.
Cancer incidence rose across the reported weight categories.
The observational study cannot establish causation.

DE

DT Editorial Team·Oct 28, 2026·via medicalxpress.com

More in Health→

Study finds a lower cancer risk after obesity surgery regardless of age or sex

Obesity Surgery Linked to Lower Cancer Risk Across Ages and Sexes

Study included more than 780,000 people with obesity in Sweden, Denmark and Finland.
Nearly 100,000 participants had undergone bariatric surgery.
Surgery was associated with an approximately 20% lower risk of obesity-related cancer.
The association was similar across age groups and sexes.

DE

DT Editorial Team·Oct 15, 2026·via medicalxpress.com

More in Health→

Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages

Daily Oral GLP-1 Orforglipron Linked to Similar Weight Loss Across Menopause Stages

Analyses of the ATTAIN-1 and ATTAIN-2 trials, led by Dr. Hunter Thomas Hoffman of Eli Lilly, will be presented at the EASD annual meeting in Milan, Italy, Sept. 28–Oct. 2.
Women taking orforglipron achieved significant, similar body weight reductions of up to 14% across premenopausal, perimenopausal and postmenopausal subgroups in both trials.
Waist circumference fell by up to 12.5 cm (4.9 inches) in orforglipron subgroups, and up to 83% of treated women lost at least 5% of body weight versus 30% on placebo.
Each menopausal subgroup receiving orforglipron or placebo contained between 142 and 225 women, and outcomes were assessed at 72 weeks.

DE

DT Editorial Team·Sep 27, 2026·via medicalxpress.com

More in Health→

New findings link obesity to loss of natural breast cancer protection

Obesity May Erase Breast Cancer's Natural Defense, Study Finds

Huntsman Cancer Institute researchers found that obesity suppresses a biological process that kills potentially cancerous cells, offering a possible explanation for obesity's link to breast cancer.
Lean breast adipocytes produce far more of the lipid 9S-HODE than obese adipocytes, and the lipid promotes ferroptosis, a form of programmed cell death.
Senior author Keren Hilgendorf said the field has focused on how obesity promotes cancer but had not considered that it may also remove a natural protection.
The team tested whether raising 9S-HODE levels in obese preclinical mouse models could restore the tumor-suppressing signal seen in lean tissue.

DE

DT Editorial Team·Sep 11, 2026·via medicalxpress.com

More in Health→

GLP-1 use among young children with obesity in US remains rare but is rising rapidly

GLP-1 Prescriptions for Young Children Are Still Rare, but the Growth Is Striking

A new national study tracks GLP-1 prescribing in U.S. children under 12 with obesity.
Use among ages 8 to 11 rose sharply from 2019 to 2026, though overall treatment remains uncommon.
Most children receiving the drugs had severe obesity and many had related health conditions.

DE

DT Editorial Team·Sep 4, 2026·via medicalxpress.com

More in Health→

GLP-1s do not cause major psychiatric harm, according to new study

Study Finds No Major Psychiatric Risk From GLP-1 Drugs

A new integrative review found no link between GLP-1 drugs and major psychiatric harm.
The analysis covered five years of mechanistic, clinical, observational and regulatory evidence.
The finding supports continued use of GLP-1 therapies with routine patient monitoring.

DE

DT Editorial Team·Sep 1, 2026·via medicalxpress.com

More in Health→

Study finds extreme obesity common among bariatric surgery patients, should not preclude treatment

Study says extreme obesity should not block bariatric surgery

Researchers analyzed 1,262,454 bariatric surgery patients from 2015 to 2023.
They found 5.3% had a BMI of 60 or higher, while about 1.1% of surgeries each year involved patients with a BMI of 70 or higher.
The study says these patients carry more complications and comorbidities, but their overall surgical risk remains relatively low and should not automatically exclude them from care.

DE

DT Editorial Team·Aug 27, 2026·via medicalxpress.com

More in Health→

New obesity definitions reveal ill health more accurately than body mass index

New Obesity Definitions Better Predict Health Risks Than BMI Alone

Study published in JAMA Network Open analyzed 2,316 bariatric surgery candidates.
Applied new obesity definitions: clinical obesity (organ damage) and preclinical obesity (preserved organ function).
73.8% had clinical obesity, 26.2% had preclinical obesity.
Clinical obesity patients had higher surgery-related and cardiovascular risks, and higher overall mortality risk.

DE

DT Editorial Team·Aug 15, 2026·via medicalxpress.com

More in Health→

Distinct brain circuits explain contradictory behaviors of new weight-loss drugs

Brain circuits may explain why opposite obesity drugs both work

Cambridge researchers used mice to explain why opposite GIPR drug strategies can both promote weight loss.
The study found that GIPR stimulation in the brainstem and GIPR blockade in the hypothalamus can produce similar outcomes.
The results may help researchers design more effective obesity drug combinations with GLP-1-based treatments.
The findings clarify mechanism, but the evidence described here is still preclinical rather than human clinical proof.

DE

DT Editorial Team·Jul 24, 2026·via medicalxpress.com

More in Health→

Injectable semaglutide shows early promise to improve fertility in women with PMOS

Injectable Semaglutide Shows Early Promise for Improving Fertility in Women with PMOS

Injectable semaglutide shows early promise for improving fertility in women with PMOS.
Study published in Fertility and Sterility from CU Anschutz.
Participants aged 12–35 who lost ≥10% body weight saw reproductive improvements.
Semaglutide may address both reproductive and metabolic symptoms of PMOS.

DE

DT Editorial Team·Jun 10, 2026·via medicalxpress.com

More in Health→

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca's Oral GLP-1 Pill Shows Promise in Mid-Stage Obesity and Diabetes Trials

AstraZeneca's oral GLP-1 pill showed 12% average weight loss in Phase 2 obesity trial.
Diabetes patients achieved significant HbA1c reductions with the once-daily pill.
Safety profile consistent with GLP-1 class; GI side effects mild to moderate.
Analysts say it's too early to compare with Novo Nordisk's Rybelsus or Lilly's orforglipron.

DE

DT Editorial Team·Jun 9, 2026·via statnews.com

More in Health→

Phase 3 trial links survodutide to liver fat and weight reductions in at-risk MASLD

Phase 3 SYNCHRONIZE-MASLD enrolled 216 adults with obesity and at-risk MASLD.
Both co-primary endpoints were met at week 48: liver fat reduction and weight loss.
Gastrointestinal side effects were most common and generally mild to moderate.

DE

DT Editorial Team·Jun 8, 2026·via nature.com

More in Health→

Scientists unlock a way to maintain GLP-1 efficacy long-term

NIH-backed research identifies a brain signaling pathway that could extend and strengthen semaglutide’s weight-loss эфф

Researchers linked semaglutide’s effect to cAMP signaling in area postrema neurons.
Some neurons sustain the response while others quickly lose it, which may help explain plateaus.
A PDE4 inhibitor, roflumilast, appeared to restore signaling in the mouse-model study.

DE

DT Editorial Team·May 28, 2026·via refractor.io

More in Innovation→

Ozempic Is Finally Turning the Tide Against Obesity, New Data Shows

GLP-1 prescribing surge coincides with a modest decline in obesity data

A large health-records dataset shows GLP-1 prescriptions rising more than fourfold since 2021.
The same dataset shows a modest decline in obesity rates over that span.
The data is early but suggests anti-obesity drugs may be shaping outcomes at scale.

DE

DT Editorial Team·May 26, 2026·via gizmodo.com

More in Culture→

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine

Oral GLP-1 candidate helps patients hold onto weight loss after injectable therapy

Phase 3b data showed oral orforglipron preserved more prior weight loss than placebo after injectable therapy.
Benefits were seen in participants previously treated with either tirzepatide or semaglutide.
The study supports an oral maintenance strategy but did not compare switching with staying on injectables.

DE

DT Editorial Team·May 13, 2026·via nature.com

More in Health→

European regulators greenlight first clinical test of GLP-1 gene therapy

Europe’s green light for Fractyl’s GLP-1 gene therapy test marks a new front in obesity medicine

European regulators cleared Fractyl Health to begin a clinical test of a GLP-1 gene therapy.
The source describes it as the first clinical test of its kind.
The effort aims at a potential one-and-done alternative to chronic GLP-1 injections or pills.
The move highlights how quickly obesity and metabolic drug development is expanding.

DE

DT Editorial Team·May 11, 2026·via endpoints.news

More in Health→

Around 8,500 steps may help people keep weight off after dieting

A meta-analysis examined 14 trials involving 3,758 participants.
Researchers found that around 8,500 steps a day may help maintain weight loss after dieting.
The study focused on the long-term problem of weight regain.
Walking may offer a practical maintenance tool alongside other obesity treatments.

DE

DT Editorial Team·May 10, 2026·via medicalxpress.com

More in Health→

New “Trojan horse” obesity drug supercharges weight loss in early tests

A ‘Trojan horse’ obesity drug outperforms standard comparators in mice

Researchers linked an incretin compound to lanifibranor in one hybrid molecule.
The treatment improved appetite, weight, and glucose outcomes in mice.
The study remains preclinical and does not yet establish human efficacy or safety.

DE

DT Editorial Team·May 9, 2026·via sciencedaily.com

More in Science→

New obesity discovery rewrites decades of fat science

Researchers Say a Fat-Burning Protein Also Protects Fat Cells From Within the Nucleus

Researchers reported that hormone-sensitive lipase operates inside adipocyte nuclei as well as on lipid droplets.
The finding may explain why HSL loss leads to lipodystrophy rather than obesity in mice and people with mutations.
The work could reshape how scientists think about adipocyte health and metabolic disease.

DE

DT Editorial Team·May 9, 2026·via sciencedaily.com

More in Science→

GLP-1 Prescriptions Surge, but Severe Obesity Still Goes Untreated

Researchers analyzed electronic health records from nearly 20 million patients with severe obesity.
GLP-1 prescriptions grew exponentially in the study population.
The study says severe obesity still often goes untreated.
The findings coincide with a decline in bariatric surgery use.

DE

DT Editorial Team·May 5, 2026·via medicalxpress.com

More in Health→

1
2
Next